{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:30:44Z","timestamp":1786653044020,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neural Regen Res"],"published-print":{"date-parts":[[2015]]},"DOI":"10.4103\/1673-5374.155443","type":"journal-article","created":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T04:48:17Z","timestamp":1430369297000},"page":"667","source":"Crossref","is-referenced-by-count":5,"title":["Effects of cilostazol on the progression and regression of symptomatic intracranial artery stenosis: it reduces the risk of ischemic stroke"],"prefix":"10.4103","volume":"10","author":[{"given":"Zhongmin","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1673-5374.155443-1","doi-asserted-by":"crossref","unstructured":"Agrawal Neeraj K, Maiti Rituparna, Dash D, Pandey BL (2007) Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol Res 56:118-123.","DOI":"10.1016\/j.phrs.2007.04.007"},{"key":"key-10.4103\/1673-5374.155443-2","unstructured":"Feng HX, Yang M, Jiang HL, Hua WZ, He JF, Yao HX, Li YB, He LX, Shi X, Yuan JQ, Liu YL (2010) Efficacy and safety in secondary prevention of ischemic stoke with cilostazol or aspirin: a systematic review. Zhongguo kangfu Lilun yu Shijian 16:961-965."},{"key":"key-10.4103\/1673-5374.155443-3","doi-asserted-by":"crossref","unstructured":"Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research (2011) Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 42:227-276.","DOI":"10.1161\/STR.0b013e3181f7d043"},{"key":"key-10.4103\/1673-5374.155443-4","doi-asserted-by":"crossref","unstructured":"Geng DF, Deng J, Jin DM, Wu W, Wang JF (2012) Effect of cilostazol on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. Atherosclerosis 220:177-183.","DOI":"10.1016\/j.atherosclerosis.2011.09.048"},{"key":"key-10.4103\/1673-5374.155443-5","doi-asserted-by":"crossref","unstructured":"Guo JJ, Xu E, Lin QY, Zeng GL, Xie HF (2009) Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. Neurosci Bull 25:383-390.","DOI":"10.1007\/s12264-009-6192-2"},{"key":"key-10.4103\/1673-5374.155443-6","doi-asserted-by":"crossref","unstructured":"H\u00e9non H, Godefroy O, Leys D, Mounier-Vehier F, Lucas C, Rondepierre P, Duhamel A, Pruvo JP (1995) Early predictors of death and disability after acute cerebral ischemic event. Stroke 26:392-398.","DOI":"10.1161\/01.STR.26.3.392"},{"key":"key-10.4103\/1673-5374.155443-7","unstructured":"Hirai T, Korogi Y, Ono K, Nagano M, Maruoka K, Uemura S, Takahashi M (2002) Prospective evaluation of suspected stenoocclusive disease of intracranial artery: combined MR angiography compared with digital subtraction angiography. AJNR 23:93-101."},{"key":"key-10.4103\/1673-5374.155443-8","doi-asserted-by":"crossref","unstructured":"Hollander M, Hak AE, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A, Witteman JC M, Breteler MMB (2003) Comparison between measures of atherosclerosis and risk of stroke: the Rotterdam study. Stroke 34:2367-2372.","DOI":"10.1161\/01.STR.0000091393.32060.0E"},{"key":"key-10.4103\/1673-5374.155443-9","doi-asserted-by":"crossref","unstructured":"Huang YN, Cheng Y, Wu J, Li YS, Xu E, Hong Z, Li ZY, Zhang WW, Ding MP, Gao XG, Fan DS, Zeng JS, Wong KS, Lu CZ, Xiao JX, Yao C, Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention cooperation investigators (2008) Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 7:494-499.","DOI":"10.1016\/S1474-4422(08)70094-2"},{"key":"key-10.4103\/1673-5374.155443-10","doi-asserted-by":"crossref","unstructured":"Ikeda (1999) Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thromb Haemost 82:435-438.","DOI":"10.1055\/s-0037-1615863"},{"key":"key-10.4103\/1673-5374.155443-11","doi-asserted-by":"crossref","unstructured":"Inoue T, Uchida T, Sakuma M, Imoto Y, Ozeki Y, Ozaki Y, Hikichi Y, Node K (2004) Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol 44:1408-1414.","DOI":"10.1016\/j.jacc.2004.06.066"},{"key":"key-10.4103\/1673-5374.155443-12","doi-asserted-by":"crossref","unstructured":"Kai Y, Watanabe M, Morioka M, Hirano T, Yano S, Ohmori Y, Kawano T, Hamada J, Kuratsu J (2011) Cilostazol improves symptomatic intracranial artery stenosis - Evaluation of cerebral blood flow with single photon emission computed tomography. Surg Neurol Int 28:8-14.","DOI":"10.4103\/2152-7806.76145"},{"key":"key-10.4103\/1673-5374.155443-13","doi-asserted-by":"crossref","unstructured":"Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS (2005) Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36:782-786.","DOI":"10.1161\/01.STR.0000157667.06542.b7"},{"key":"key-10.4103\/1673-5374.155443-14","doi-asserted-by":"crossref","unstructured":"Lee JH, Park SY, Shin YW, Hong KW, Kim CD, Sung SM, Kim KY, Lee WS (2006) Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res 1082:182-191.","DOI":"10.1016\/j.brainres.2006.01.088"},{"key":"key-10.4103\/1673-5374.155443-15","unstructured":"Li JB, Huang L (2008) The progress of research on aspirin resitance. Zhongguo Xunhuan Zazhi 23:314-316."},{"key":"key-10.4103\/1673-5374.155443-16","doi-asserted-by":"crossref","unstructured":"Matsumoto M (2005) Cilostazol in secondary prevention of stroke:impact of the cilostazol stroke prevention study. Atheroscler Suppl 6:33-40.","DOI":"10.1016\/j.atherosclerosissup.2005.09.003"},{"key":"key-10.4103\/1673-5374.155443-17","doi-asserted-by":"crossref","unstructured":"Mazighi M, Tanasescu R, Ducrocq X, Vicaut E, Bracard S, Houdart E, Woimant F (2006) Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology 66:1187-1191.","DOI":"10.1212\/01.wnl.0000208404.94585.b2"},{"key":"key-10.4103\/1673-5374.155443-18","doi-asserted-by":"crossref","unstructured":"Park SW, Lee CW, Kim HS, Lee NH, Nah DY, Hong MK, Kim JJ, Park SJ (2000) Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol 86:499-503.","DOI":"10.1016\/S0002-9149(00)01001-8"},{"key":"key-10.4103\/1673-5374.155443-19","doi-asserted-by":"crossref","unstructured":"Park SY, Shin HK, Lee JH, Kim CD, Lee WS, Rhim BY, Hong KW (2009) Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db\/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription. J Pharmacol Exp Ther 329:571-579.","DOI":"10.1124\/jpet.108.146456"},{"key":"key-10.4103\/1673-5374.155443-20","doi-asserted-by":"crossref","unstructured":"Porto I, D\u2032Amario D, Crea F (2012) Cilostazol and primary-PCI: mirage or good alternative? Curr Vasc Pharmacol 10:468-471.","DOI":"10.2174\/157016112800812854"},{"key":"key-10.4103\/1673-5374.155443-21","doi-asserted-by":"crossref","unstructured":"Qian Y, Bi Q (2013) Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. Eur J Med Res 18:53.","DOI":"10.1186\/2047-783X-18-53"},{"key":"key-10.4103\/1673-5374.155443-22","doi-asserted-by":"crossref","unstructured":"Sacco RL, Kargman DE, Gu Q, Zamanillo MC (1995) Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke 26:14.","DOI":"10.1161\/01.STR.26.1.14"},{"key":"key-10.4103\/1673-5374.155443-23","doi-asserted-by":"crossref","unstructured":"Sallustio F, Rotondo F, Di Legge S, Stanzione P (2010) Cilostazol in the management of atherosclerosis. Curr Vasc Pharmacol 8:363-372.","DOI":"10.2174\/157016110791112331"},{"key":"key-10.4103\/1673-5374.155443-24","doi-asserted-by":"crossref","unstructured":"Shin HK, Kim YK, Kim KY, Lee JH, Hong KW (2004) Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lection-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 109:1022-1028.","DOI":"10.1161\/01.CIR.0000117403.64398.53"},{"key":"key-10.4103\/1673-5374.155443-25","doi-asserted-by":"crossref","unstructured":"Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C, CSPS 2 group (2010) Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9:959-968.","DOI":"10.1016\/S1474-4422(10)70198-8"},{"key":"key-10.4103\/1673-5374.155443-26","doi-asserted-by":"crossref","unstructured":"Symeonidis A, Kouraklis-Symeonidis A, Seimeni U, Galani A, Giannakoulas N, Fragopanagou E, Tiniakou M, Matsouka P, Zoumbos N (2002) Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases. Am J Hematol 71:24-32.","DOI":"10.1002\/ajh.10150"},{"key":"key-10.4103\/1673-5374.155443-27","doi-asserted-by":"crossref","unstructured":"Szczeklik A, Musial J, Undas A, Sanak M, Nizankowski R (2005) Aspirin resistance. Pharmacol Rep 57 Suppl:33-41.","DOI":"10.1111\/j.1538-7836.2005.01372.x"},{"key":"key-10.4103\/1673-5374.155443-28","doi-asserted-by":"crossref","unstructured":"Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, Tamai T, Nakai T, Miyabo S (1992) Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of smooth muscle cell culture. J Cardiovasc Pharmacol 20:900-906.","DOI":"10.1097\/00005344-199212000-00009"},{"key":"key-10.4103\/1673-5374.155443-29","doi-asserted-by":"crossref","unstructured":"Urbano LA, Bogousslavsky J (2004) Antiplatelet drugs in ischemic stroke prevention: from monotherapy to combined treatment. Cerebrovasc Dis 17:74-80.","DOI":"10.1159\/000074800"},{"key":"key-10.4103\/1673-5374.155443-30","doi-asserted-by":"crossref","unstructured":"Wong KS, Li H (2003) Long-term mortality and recurrent stroke risk among Chinese stroke patients with predominant intracranial atherosclerosis. Stroke 34:2361.","DOI":"10.1161\/01.STR.0000089017.90037.7A"},{"key":"key-10.4103\/1673-5374.155443-31","doi-asserted-by":"crossref","unstructured":"Yamada K, Fujimoto Y (2011) Efficacy of cilostazol for intracranial arterial stenosis evaluated by digital subtraction angiography\/magnetic resonance angiography. Adv Ther 28:866-878.","DOI":"10.1007\/s12325-011-0060-y"},{"key":"key-10.4103\/1673-5374.155443-32","unstructured":"Yan Q, Shi ZH, Yang KH, Yian JH (2011) Cilostazol for preventing ischemic stroke recurrence. Zhongguo Xunzheng Yixue Zazhi 11:540-544."}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:30:34Z","timestamp":1786649434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.155443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"alternative-id":["155443"],"URL":"https:\/\/doi.org\/10.4103\/1673-5374.155443","relation":{},"ISSN":["1673-5374"],"issn-type":[{"value":"1673-5374","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}